Company Description
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers.
The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity.
The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Country | United States |
Founded | 1998 |
IPO Date | May 2, 2019 |
Industry | Medical Devices |
Sector | Healthcare |
Employees | 584 |
CEO | Dr. Waleed H. Hassanein M.D. |
Contact Details
Address: 200 Minuteman Road Andover, Massachusetts 01810 United States | |
Phone | (978) 552-0900 |
Website | transmedics.com |
Stock Details
Ticker Symbol | TMDX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $16.00 |
CIK Code | 0001756262 |
CUSIP Number | 89377M109 |
ISIN Number | US89377M1099 |
SIC Code | 3845 |
Key Executives
Name | Position |
---|---|
Dr. Waleed H. Hassanein M.D. | Founder, President, Chief Executive Officer and Director |
Stephen Gordon | Chief Financial Officer, Treasurer and Secretary |
Dr. Tamer I. Khayal M.D. | Chief Commercial Officer |
Miriam C. Provost Ph.D. | Vice President of Global Regulatory Affairs |
Nicholas Corcoran | Senior Vice President of Supply Chain and Operations |
Mark Anderson | Senior Director of Technology Development |
Anil Ranganath | Senior Vice President, General Counsel and Corporate Secretary |
Susan Goodman | Vice President of Human Resources |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 10, 2024 | 144 | Filing |
Apr 10, 2024 | ARS | Filing |
Apr 10, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Apr 10, 2024 | DEF 14A | Other definitive proxy statements |
Apr 8, 2024 | 144 | Filing |
Apr 3, 2024 | 144 | Filing |
Apr 1, 2024 | 144 | Filing |
Mar 18, 2024 | 144 | Filing |
Mar 18, 2024 | 144 | Filing |
Mar 13, 2024 | 144 | Filing |